Anti-Human Flt-3/Flk-2 Reference Antibody (AGS62P1, RUO) (HW794026)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HW794026
Description	Anti-Human CD135/FLT3 (AGS62P1) (HW794026) is a research-grade recombinant antibody targeting CD135. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	AGS62P1
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	FLT3, Stem cell tyrosine kinase 1, Fetal liver kinase-2, STK-1, STK1, FLK2, CD135, Receptor-type tyrosine-protein kinase FLT3, Fms-like tyrosine kinase 3, FL cytokine receptor, FLK-2, FLT-3
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P36888
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	AGS62P1
Background	Receptor-type tyrosine-protein kinase FLT3 (CD135) is a ~112 kDa protein. Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B.
Note	For research use only. Not suitable for clinical or therapeutic use.